• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

TVM Capital Life Science Venture Capital

Investing in Life Science Innovation

  • About Us
    • Partners
  • Team
  • Senior Advisors
  • Portfolio
  • Funding Request
  • News
  • Events
  • ESG Policy
  • Contact

News

  • Home
  • About Us
  • Team
  • Senior Advisors
  • Portfolio
  • News
  • Events
  • ESG Policy
  • Contact

News

News · October 8, 2021

CENTOGENE and Twist Bioscience to Develop Advanced Sequencing Tools to Make Genetic Testing Rapidly Accessible for More Patients With Rare Diseases

centogene

Combining Expertise to Advance Precision Medicine, While Enabling a More Efficient and Timely Diagnosis of Rare Diseases Around the World CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN and SOUTH …

News · October 8, 2021

Acer Therapeutics Receives Notice of Allowance of Key U.S. Patent Application Covering ACER-001 Formulation

laboratory

Notice of allowance of ACER-001 formulation composition of matter patent application strengthens proprietary position in U.S. until 2036 NEWTON, MA and GENEVA, SWITZERLAND – October 7, 2021 – Acer …

News · July 15, 2021

Rapid Micro Biosystems Announces Pricing of Initial Public Offering

Source: Rapid Micro Biosystems, Inc.July 14, 2021 21:30 ETLOWELL, Mass., July 14, 2021 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (“RapidMicro”), an innovative life sciences …

News · May 27, 2021

Acer Therapeutics Plans NDA Submission for ACER-001 in Q3 2021
Following Pre-NDA Meeting with FDA

laboratory

NEWTON, MA and GENEVA, SWITZERLAND – May 25, 2021 – Acer Therapeutics Inc. (Nasdaq: ACER)(“Acer”), a pharmaceutical company focused on the acquisition, development and commercialization of therapies …

News · March 25, 2021

COVID Innovations March 25th, 2021

Author: Dr. Linda Morrow – March 25th, 2021 Imagine a pandemic without having to shut down our lives. Imagine governments and industry working cooperatively to develop diagnostic and vaccine …

News · March 22, 2021

Relief and Acer Therapeutics Sign Collaboration and License Agreement for Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease

laboratory

Relief to potentially pay Acer up to $36 million and royalties in exchange for net profit share and territory rights ACER-001 pre-NDA meeting with U.S. FDA scheduled in Q2 2021 GENEVA, SWITZERLAND and …

  • « Go to Previous Page
  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to page 4
  • Go to page 5
  • Go to page 6
  • Interim pages omitted …
  • Go to page 51
  • Go to Next Page »

Primary Sidebar

Secondary Sidebar

Additional News

TVM Capital Life Science to participate in LSI USA ’23 Emerging Medtech Summit 2023

March 17, 2023

TVM Capital Life Science Announces Promotions to Recognize Significant Contributions of Up-and-Coming Leaders

February 23, 2023

Esperas Pharma, Inc. Announces Investment from TVM Life Science Innovation I and The Fonds de solidarité FTQ

February 21, 2023

TVM Capital Life Science announces up to USD 24 million investment in oncology company, Recurv Pharma, Inc.

February 1, 2023

Panthera D-SAD Classic oral appliance now eligible for Medicare reimbursement

August 1, 2022

  • in

Copyright © 2023 · TVM Capital Life Science Venture Capital · ESG Disclosure · Privacy Policy · Contact